Clinical Report: Modulating the Gut-Heart Connection with Danggui Sini Granule
Overview
This study investigates the effects of Danggui Sini Granule (DSG) on vasospastic coronary heart disease (CHD) in a rat model. DSG demonstrated cardioprotective effects through modulation of gut microbiota, lipid metabolism, and inflammation pathways.
Background
Coronary heart disease (CHD) is a leading cause of morbidity and mortality globally, with persistent cardiovascular risk despite standard therapies. The gut-heart axis has emerged as a potential therapeutic target, as gut microbial dysbiosis can influence cardiovascular health. Understanding the mechanisms by which interventions like DSG affect this axis may enhance CHD management.
Data Highlights
Parameter
Effect of DSG
ST-segment elevation
Attenuated
Myocardial histopathological injury
Reduced
Systemic inflammatory mediators (TNF-α, IL-6)
Lowered
Opportunistic/pathogenic genera
Reduced
Beneficial taxa (Lactobacillus, Clostridium)
Enriched
Key Findings
DSG reduced ST-segment elevation in a rat model of vasospastic CHD.
Histopathological injury to the myocardium was significantly mitigated by DSG treatment.
DSG lowered levels of systemic inflammatory markers, including TNF-α and IL-6.
Microbiota analysis revealed a reduction in pathogenic genera and an increase in beneficial taxa.
Metabolomics indicated restoration of protective lipid mediators associated with cardiovascular health.
Clinical Implications
The findings suggest that DSG may provide a multifaceted approach to managing vasospastic CHD by targeting gut microbiota and metabolic pathways. Further research is needed to validate these mechanisms and their clinical relevance.
Conclusion
DSG shows promise in providing cardioprotective effects in vasospastic CHD through gut-heart-axis modulation. Future studies should focus on establishing causal relationships in these observed effects.
Dr. Uprety discusses the current role of non-invasive testing for coronary artery disease, highlighting evidence-based diagnostic strategies and the appropriate use of imaging modalities to improve early detection, risk stratification, and clinical decision-making.
Damon B. Dixon, MD, at Phoenix Children’s Cardiology, is the author to this EndoText chapter. Dr. Dixon brings nationally recognized expertise in pediatric cardiovascular risk assessment and non?invasive vascular imaging.
